Synovial sarcoma
Jump to navigation
Jump to search
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
| Last updated on 2024-11-20: 1 regimens on this page
1 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
Advanced or metastatic disease, subsequent lines of therapy
Afamitresgene autoleucel monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| D'Angelo et al. 2024 (SPEARHEAD-1) | 2019-12-17 to 2021-07-27 | Phase 2 (RT) |
Preceding treatment
- Lymphodepletion with FC
Targeted therapy
- Afamitresgene autoleucel (Tecelra) 1 x 109 to 10 x 109 T cells IV once on day 0
One course
References
- SPEARHEAD-1: D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13;403(10435):1460-1471. Epub 2024 Mar 27. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT04044768